Perfusion Bioreactors: Continuous Cell Culture and High Cell Density

Continuous biomanufacturing is an integrated manufacturing approach that extends from upstream perfusion systems (originally developed in the 1980s for unstable molecules) to downstream processing and formulation, offering significant cost reductions through space optimization and time savings by enabling continuous pilot operations for clinical trial materials; successful implementation requires a strategic, step-by-step approach starting with upstream perfusion, then integrating downstream capture steps, followed by formulation, while addressing key challenges including quality system requirements, process characterization with residence time distribution evaluation, regulatory compliance under guidelines like ICH Q13, and demonstrating process stability over time to ensure product consistency.

Continuous counter-current chromatography offers a quasi-continuous downstream purification approach: (1) Upstream perfusion cultures steadily remove harvested cells using retention devices, (2) Downstream processing traditionally uses batch chromatography with hold times between steps, (3) Continuous counter-current chromatography connects multiple columns in series where one column loads while another washes and equilibrates simultaneously, (4) This eliminates downtime between column cycles, enabling continuous product elution over larger surface areas, (5) The system can integrate anion exchange, affinity, and polishing steps in sequence without intermediate storage.

Next-generation biomanufacturing focuses on four key business drivers—increased speed, flexibility, product quality, and reduced costs—through advanced upstream processes like perfusion and intensified fed-batch for seed trains and production, and downstream innovations including continuous multi-column chromatography (2-8x productivity gains) and membrane chromatography (20-50x productivity gains), ultimately integrating upstream, downstream, and inline process analytics into fully continuous manufacturing processes.

Continuous counter-current chromatography, while well-established at lab scale, requires further development for large-scale GMP manufacturing, particularly in areas of model-based process validation, automation, and digitalization; the technology offers significant advantages over traditional batch chromatography but must overcome regulatory and operational challenges to achieve widespread industrial adoption.

Perfusion technology enables continuous harvesting of product from bioreactors by continuously replenishing fresh media to sustain cell health while simultaneously removing spent media and harvested product. This approach allows cells to remain in a healthy state while producing therapeutic proteins. The continuously harvested product then flows directly into downstream purification systems without lingering in hold vessels for extended durations. This eliminates quality risks associated with prolonged storage and provides particular benefits for sensitive biological products that may degrade under certain environmental conditions.

Process analytical technologies, particularly capacitance probes for real-time viable cell density monitoring, enable efficient optimization of perfusion processes by allowing inline adjustment of cell-specific perfusion rates (CSPR), which reduces media usage by approximately 25% compared to fixed volumetric perfusion strategies while maintaining high cell densities and viabilities; this approach streamlines platform development workflows, enabling new monoclonal antibody programs to reach manufacturing readiness within 2-3 experiments rather than extensive optimization studies.

Control loops in steady-state simulators determine final steady-state values but cannot capture dynamic transient behavior. They automate process optimization: for heat exchangers, they adjust heating medium flow rates to maintain target temperatures; for reactors, they adjust reactor length to achieve desired conversion. Implementation requires creating information ports on operations to send/receive data, configuring controllers to connect these ports, and setting appropriate unit conversions. COCO simulates measurement devices through information elements measuring temperature, pressure, or component flow rates. However, steady-state simulators only provide final equilibrium values, not dynamic response curves. When set-points change, the simulator shows only the new equilibrium, not the time-dependent trajectory. This is a fundamental limitation of steady-state simulation, as it cannot capture dynamic behavior visible in dynamic simulators.

Traditional validation based on strict rules has generated excessive paperwork without proportional benefit. Phases lasting weeks to months with costs reaching millions of dollars delay operations. Pharmaceutical water systems are dynamic and continuous, unlike batch processes. Traditional discrete monitoring applies inappropriate statistical methods to continuous flows. Process Analytical Technology (PAT) provides real-time measurements during processing to understand and control quality attributes. When processes are under control, product quality is consistent, eliminating waste, rejects, rework, and OOS situations.

Process Analytical Technology (PAT) is a data-driven approach for batch modeling and process control, evolving from Process Analytical Chemistry (PAC) to encompass optimization of energy, time, and raw materials. The FDA's 2004 initiative established PAT as a framework for innovative pharmaceutical development, manufacturing, and quality assurance. PAT encompasses goals of process understanding, optimization, and improving robustness using Quality by Design (QbD). The tools include process analytical sensors, process control tools, and multivariate tools for design and data analysis. The three-step analytical approach involves: (1) multivariate calibrations on CQAs using rapid measurements like NIR or Raman spectroscopy, (2) Multivariate Statistical Process Control (MSPC) extending classical SPC to handle correlated variables and prevent false alerts, and (3) Batch Process Control (BSPC) applying MSPC to batch processes with time kinetics.

Implementing Process Analytical Technology requires a systematic approach involving cultural transformation, building cross-functional teams, selecting appropriate instrumentation and software (including MVA and knowledge management platforms), conducting designed experiments to build predictive models, validating these models, and using them to develop mechanistic understanding and control algorithms that enable real-time quality monitoring and significantly reduce scale-up time from pilot to production.

Regulatory definitions emphasize uniform character and quality from a single manufacturing cycle, with no distinction between batch and lot methods. Continuous manufacturing enables flexible batch sizing based on demand but requires proper definition as a function of runtime or material quantity. Not all unit operations achieve state of control simultaneously during startup and shutdown; procedures must define when to begin/stop collecting product and divert material when not in control. Time release testing leverages continuous data streams to enhance product understanding and quality assurance. Design considerations include risk-based sampling point selection, system dynamics-supported strategies, preventing interface fouling, and ensuring representative sampling. Spectroscopy models require proper development, validation, and procedures for maintaining currency.

FDA defines batch as quantity produced under single order with uniform quality; lot as identified amount produced in unit time for continuous processes. Documentation requirements include specification testing, production records, discrepancy investigations, and recall systems—all applicable to continuous operations. Polishing uses membrane absorbers (Mustang Q anion exchange, CMC Hypercell cation exchange). Clarification differs: acoustic separation handles fed-batch; perfusion requires specialized acoustic systems plus sterilizing filters. Column configuration optimizes productivity: more columns handle higher titers, with eight providing maximum flexibility. Economic adoption depends on context—new facilities or clinical programs favor continuous, while established blockbusters face high transition barriers.

The first critical decision in process design is selecting between batch and continuous processing. Batch processes handle discrete material quantities over defined periods, while continuous processes feed material continuously through equipment. Key factors favoring batch processing include small material volumes, strict product accountability (critical for FDA-certified foods and drugs), flexibility for modifications, seasonal feedstock availability, slow reactions requiring long residence times, equipment fouling concerns, safety requirements, and operator training challenges. Continuous processing is preferred for large volumes, time and cost savings, operational efficiency, energy minimization, reduced maintenance, easier process control, and stable long-term operation. Economics typically drive the choice toward continuous processes unless specific batch requirements exist.

Continuous manufacturing in pharmaceutical production requires defining batch size before operation and ensuring product collection occurs when the process is in a state of control, with cleaning principles similar to batch manufacturing but requiring special considerations for smaller equipment; while existing FDA guidelines are similar to batch manufacturing, some policy considerations like continuous process verification and performance-based approaches require further discussion and may not be directly applicable to biological products.

Continuous manufacturing (CM) is a process-based approach where materials come in, undergo transformation, and go out simultaneously, contrasting with traditional batch processing. CM offers benefits including increased efficiency, flexibility, agility, robustness, integrated processing with fewer steps, smaller footprint, and real-time quality assurance. The FDA has approved five CM applications between 2015-2017 and two in 2018. In February 2019, FDA published a draft guidance on quality considerations for CM of small molecules solid oral dosage products, representing a move toward integrating CMC and cGMP concepts under a unified quality voice. The guidance received 24 letters from industry stakeholders with nearly 400 comments consolidated into 44 categories. Key considerations include process validation benefits, data integrity for online monitoring systems, runtime extension evaluation during PPQ stage, and material diversion protocols.